Matches in Nanopublications for { ?s ?p "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP720723.RAkswjyZP3dxI8zcChOnm5iw96JmgtyXWBgASaAfDkVjU130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP720723.RAkswjyZP3dxI8zcChOnm5iw96JmgtyXWBgASaAfDkVjU130_provenance.
- NP899916.RAstr3Kwr1e2AJtBv0z7N8gfKNJlW7tWHkWZ0wlSona3s130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP899916.RAstr3Kwr1e2AJtBv0z7N8gfKNJlW7tWHkWZ0wlSona3s130_provenance.
- NP450644.RAw0T9RYqkECdKYig3qJUez19Qxef6YJKlj6UByshyeRo130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP450644.RAw0T9RYqkECdKYig3qJUez19Qxef6YJKlj6UByshyeRo130_provenance.
- NP666081.RA3FofhM76OrpZsSVwPugla4kthamasqTIN4trOX8paOw130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666081.RA3FofhM76OrpZsSVwPugla4kthamasqTIN4trOX8paOw130_provenance.
- NP666098.RA8Vz6ocUp9AudwM_DWGdOnsbOq7Wfm-lQw386T1aQbu4130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666098.RA8Vz6ocUp9AudwM_DWGdOnsbOq7Wfm-lQw386T1aQbu4130_provenance.
- NP797019.RAQ2s0XvaTH2RX31vtGlyEHTT1xXFQTG93fieACWU0Y-8130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP797019.RAQ2s0XvaTH2RX31vtGlyEHTT1xXFQTG93fieACWU0Y-8130_provenance.
- NP797024.RAcQc01FNije8V4QIOozqdYZOxNs7vI1YxS5xSBJJXAJo130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP797024.RAcQc01FNije8V4QIOozqdYZOxNs7vI1YxS5xSBJJXAJo130_provenance.
- assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP797021.RAIHCvMCAjMHC0wq8F0UHvCp97E6uGjM9BEqM9PNsI5uk130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP797021.RAIHCvMCAjMHC0wq8F0UHvCp97E6uGjM9BEqM9PNsI5uk130_provenance.
- NP666037.RAhGD7SvcJdamxWT75VrljOFrwJLzHqipONq-_sq42YUU130_assertion description "[Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666037.RAhGD7SvcJdamxWT75VrljOFrwJLzHqipONq-_sq42YUU130_provenance.